Otsuka Targets Apotex In Latest Suit Over Generic Abilify

Law360, New York (September 12, 2012, 1:10 PM EDT) -- Otsuka Pharmaceutical Co. Ltd. on Monday continued in its crusade to protect the patents underlying the drug Abilify, alleging in New Jersey federal court that Apotex Corp. is attempting to bring a generic version of the schizophrenia treatment to market before these patents expire.

In its latest attempt to protect the intellectual property associated with its schizophrenia drug, Otsuka alleges that its generic competitor is seeking approval from the U.S. Food and Drug Administration to sell a knockoff version of Abilify. Otsuka said that if Apotex...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.